Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Lung06 first-line HER2-overexpressing non-squamous NSCLC trial
2024-515658-26-00Phase 3Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan, pembrolizumab, carboplatin, cisplatin and pemetrexed in Non-small cell lung cancer (NS-NSCLC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival. Planned start Jan 2026; status: authorised.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515658-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515658-26-00.